Highest-materiality recent filing
Weight Watchers Q2 revenue $162.3M, clinical subscribers up 55.7% YoY; reaffirms FY guidance
Q2 revenue $162.3M (down 14% YoY); clinical subscription revenue $39.9M, up 30.4% YoY.
WW International settles with former CEO Tara Comonte for $1.85M
Settlement payment of $1,850,000 in two installments: $545,205.48 now, $1,304,794.52 by Oct 1, 2026.
Q1 revenue $168M, net loss $52M; adjusted EBITDA loss $1.8M vs prior adj EBITDA $26.9M (not comparable due to fresh start accounting).
WW CEO Tara Comonte resigns; OCEO established; legal chief Cooke departs with $1.5M separation
CEO Tara Comonte resigned March 31, 2026; Board established Office of the CEO with CFO DellaFortuna and COO Volkmann effective April 3.
Weight Watchers Q4 rev $163M, net loss $6M; clinical subs up 42%; FY2026 rev guidance $620-635M
Q4 total revenue $163M (-12% YoY); net loss $6M vs income $25M YoY; adjusted EBITDA $18M (11.1% margin).
WeightWatchers Q3 net loss $58M, revenue $172M; narrows FY guidance to higher end
Total revenue $172M, down 10.8% YoY; clinical subscription revenue $26M, up 35.3% YoY.
WeightWatchers emerges from reorganization, cuts debt $1.15B; Q2 combined revenue down 6%
Completed strategic reorganization on June 24, reducing debt by $1.15 billion and applying fresh-start accounting.
Completed financial reorganization with enhanced flexibility; relisted on Nasdaq under ticker WW on July 8, 2025.
WW International exits Chapter 11; old equity canceled, $465M new term loan, new board
Emergence effective June 24, 2025; old common stock canceled, holders receive 900,000 of 10M new shares (9%).
Court confirmed prepackaged plan on June 17, 2025; exit expected on or about June 24, 2025.
WW International files amended Chapter 11 plan; existing equity to get 9% of new common
Amended Plan Supplement filed June 12: existing equity holders receive 9% of new common equity, subject to milestones; first lien holders get 91%.
WW International files amended Chapter 11 plan; takeback debt all term loans; stock delisted to OTC
Nasdaq delisting effective after Form 25; stock now trades OTC under WGHTQ since May 16.
Nasdaq notified WW on May 9, 2025, that its common stock will be delisted following the Chapter 11 filing on May 6.
Filed Chapter 11 on May 6, 2025 with prepackaged plan supported by 72% of First Lien Creditors.
WW Q1 revenue down 9.7% to $186.6M; clinical revenue up 57%; in debt restructuring talks
Net loss improved to $72.6M ($0.91 EPS loss) from $347.9M ($4.39) YoY.
WW International receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Received Nasdaq letter on March 19, 2025 for failure to maintain minimum $1.00 bid price.
WW International Q4 net income $25.1M vs loss; names Tara Comonte permanent CEO
Q4 revenue $184.4M (-10.5% YoY); subscription rev down 7.3%; clinical subscription rev $20.5M (+57.9%).
WW International borrows remaining $121.3M under revolver; total debt $175M
Borrowed $121.3M, the full remaining capacity under senior secured revolver on Jan 31, 2025.
WW International appoints Felicia DellaFortuna as CFO, replacing Heather Stark effective Jan 1, 2025
Heather Stark to cease as CFO on Dec 27, 2024; she receives $884,293 cash severance plus benefits, subject to release.
WW International Q3 revenue $192.9M, operating loss $39M; subscribers down 8.8%
Revenue $192.9M (-10.2% YoY); subscription revenue $191.2M (-6.0%).
WW CEO Sistani departs; board member Comonte appointed interim CEO; FY2024 guidance reaffirmed
Sistani steps down as CEO and director effective Sept 27; receives severance, transition services, coaching ($37.5k), and legal fees ($50k).
WeightWatchers Q2 revenue down 10.9% to $202.1M, announces $100M restructuring plan, CTO departs
Revenues $202.1M (down 10.9% YoY); net income $23.3M (down 54.2%); EPS $0.29 (down 54.9%).
WW Q1 2024: Revenue $206.5M, op loss $269.3M on $258M impairment; subscriber flat 4.0M
Revenue $206.5M (-14.6% YoY); subscription revenue $204.1M (-3.3%); other revenue $2.5M (-92%).
WW on track to beat Q1 fiscal 2024 guidance for Clinical subscribers
Company disclosed to employees it expects to exceed previously issued Q1 2024 guidance for end-of-period Clinical subscribers.
WW Q4 net loss $88.1M (-$1.11 EPS); Oprah Winfrey leaves board, donates stock
Q4 revenue $206.0M (down 7.6% YoY); net loss $88.1M vs $35.8M loss in prior year.
WW Q3 revenue $214.9M (-14% YoY); subscriber growth 6% to 4.0M; FY guidance narrowed
Revenue $214.9M (-14% YoY); subscription revenue $203.5M (-7.8%); product sales down 61%.
WW International Q2 revenue falls 15.8% to $226.8M; subs grow sequentially
Q2 revenues $226.8M, down 15.8% YoY; operating income $26.3M vs $13.4M prior year.
Weekend Health's 2022 revenue $6.28M (subscriptions $4.65M); net loss $17.46M ($15.1M from SAFE revaluation).
WW International reports Q1 operating loss of $28.6M, revenue falls 18.8% YoY
Q1 revenue $241.9M, down 18.8% YoY; operating loss $28.6M vs $9.0M profit last year.
WW International completes $132M acquisition of telehealth platform Sequence
Total consideration $132M: ~$64.2M cash (incl. $25.8M of Sequence cash), ~$34.7M stock (8M shares at $4.34), plus $16M deferred on each of Apr 10, 2024 and 2025.
Tara Comonte, the Company’s former President and Chief Executive Officer, resigned from her position as President and Chief Executive Officer of the Company, effective March 31, 2026.
On November 27, 2024, WW International, Inc. (the “Company”) announced that it had mutually agreed with Heather Stark, Chief Financial Officer of the Company, that she would cease serving as the Company’s Chief Financial Officer, effective December 27, 2024
On November 27, 2024, the Company also announced the appointment of Felicia DellaFortuna to serve as its Chief Financial Officer, effective January 1, 2025
On September 26, 2024, the Board appointed Tara Comonte as Interim President and Chief Executive Officer, effective September 27, 2024, to serve until a permanent President and Chief Executive Officer is identified.
On September 26, 2024, WW International, Inc. (the “Company”) and Sima Sistani, the Company’s President and Chief Executive Officer, mutually agreed that Ms. Sistani would cease serving as the Company’s President and Chief Executive Officer, effective September 27, 2024.
the elimination of the position of Chief Technology Officer effective August 9, 2024 and the related departure from the Company of Pierre-Olivier Latour
On May 21, 2024, WW International, Inc. (the “Company”) announced that Amanda Tolleson, Chief Marketing Officer of the Company, would be leaving the Company on June 4, 2024 (the “Departure Date”).
On February 26, 2024, Oprah Winfrey notified the Chairman of the Company’s Board of Directors (the “Board”) that she would not be standing for re-election as a member of the Board at the Company’s 2024 annual meeting of shareholders.
On November 29, 2023, WW International, Inc. (the “Company”) announced that Michael F. Colosi, General Counsel and Secretary of the Company, would be leaving the Company on December 29, 2023 (the “Departure Date”).
Effective August 24, 2023, the Company appointed Nicole Haag, the Company’s Vice President, Internal Audit, as Corporate Controller and Principal Accounting Officer.
On August 23, 2023, WW International, Inc. (the “Company”) announced that effective as of 11:59 p.m. on that same date, Amy Kossover resigned as Senior Vice President, Corporate Controller and Principal Accounting Officer of the Company and will leave the Company on September 1, 2023.
On July 31, 2023, Jennifer Dulski notified the Secretary of WW International, Inc. (the “Company”) of her resignation as a director of the Company, effective as of 11:59 p.m. on August 4, 2023.
Max materiality 1.00 · Median 0.65 · Most common event leadership